SCHEMBL4828806

SCHEMBL4828806

COc1ccc(N2C(N)=c3ccoc3=NC2c2cccc(C(=O)Nc3cccnc3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.50
▸ RAB9A P51151 2/20 0.48
▸ KMT2A Q03164 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ CSF1R P07333 1/20 0.45
▸ TSHR P16473 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ BRAF P15056 1/20 0.43
▸ PKM P14618 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4830808 0.91 KMT2A (0.42) ALDH1A1RAB9AKMT2APOLBSMN1; SMN2
SCHEMBL4836536 0.84 L3MBTL1 (0.39) ALDH1A1POLBTSHRLMNAMAPK1
SCHEMBL4835654 0.83 PARP1 (0.39) ALDH1A1KMT2APOLBLMNAGAA
SCHEMBL4833358 0.83 PDE5A (0.38) ALDH1A1RAB9AKMT2ASMN1; SMN2PKM
SCHEMBL4835178 0.83 ACSS2 (0.37) ALDH1A1RAB9AKMT2APOLBTSHR
SCHEMBL4833764 0.83 ABCB1 (0.39) ALDH1A1RAB9AKMT2APOLBTSHR
SCHEMBL4831236 0.83 KMT2A (0.46) ALDH1A1RAB9AKMT2APOLBTSHR
SCHEMBL4836762 0.82 ALDH1A1 (0.43) ALDH1A1RAB9AKMT2ASMN1; SMN2LMNA
SCHEMBL4836179 0.82 CSF1R (0.45) ALDH1A1RAB9AKMT2APOLBCSF1R
SCHEMBL4833975 0.81 KDM4E (0.46) ALDH1A1RAB9AKMT2APOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK ALDH1A1 906/4885RAB9A 3248/4885KMT2A 324/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR ALDH1A1 1144/4885RAB9A 4166/4885KMT2A 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback